LYPLAL1

Across TCGA pan-cancer cohorts, LYPLAL1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LYPLAL1 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LYPLAL1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LYPLAL1 expression acts as an unfavorable survival marker.

HNSC, READ, and UCEC are the cancer types where LYPLAL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.079	0.746	<.001	36	view →
READ	OS	Median	II,III,IV	0.054	0.934	<.001	24	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
PRAD	DFS	Median	All	0.224	0.775	.033	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LYPLAL1–HNSC (OS)

Open the HNSC breakdown →